These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 12641482)

  • 1. Statin therapy in the elderly: does it make good clinical and economic sense?
    Mungall MM; Gaw A; Shepherd J
    Drugs Aging; 2003; 20(4):263-75. PubMed ID: 12641482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and economic evaluation of statins for the prevention of coronary events.
    Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
    Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
    Maroo BP; Lavie CJ; Milani RV
    Drugs Aging; 2008; 25(8):649-64. PubMed ID: 18665658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
    Coukell AJ; Wilde MI
    Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pravastatin: a review of its use in elderly patients.
    Bang LM; Goa KL
    Drugs Aging; 2003; 20(14):1061-82. PubMed ID: 14651445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
    Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
    Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a model to project the long-term benefit and cost of alternative lipid-lowering strategies in patients with hypercholesterolaemia.
    Cook JR; Yin D; Alemao E; Drummond M
    Pharmacoeconomics; 2004; 22 Suppl 3():37-48. PubMed ID: 15669152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study of pravastatin in the elderly at risk: new hope for older persons.
    Shepherd J
    Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):17-24. PubMed ID: 15133425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering drug therapy in elderly patients.
    Berthold HK; Gouni-Berthold I
    Curr Pharm Des; 2011; 17(9):877-93. PubMed ID: 21418034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
    Pignone M; Earnshaw S; Tice JA; Pletcher MJ
    Ann Intern Med; 2006 Mar; 144(5):326-36. PubMed ID: 16520473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.
    Lim SS; Vos T; Peeters A; Liew D; McNeil JJ
    Med J Aust; 2001 Nov; 175(9):459-64. PubMed ID: 11758073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiating statins in the elderly: the evolving challenge.
    Walker DB; Jacobson TA
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):182-7. PubMed ID: 18316955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
    Frisinghelli A; Mafrici A
    Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women.
    Seed M
    Atheroscler Suppl; 2002 May; 3(1):53-63. PubMed ID: 12044587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.